Daily aspirin in adults with type 2 diabetes
Treatments studied
Part of Hormones & metabolism clinical trials.
This early-stage study tests how a daily aspirin tablet behaves in the body and how it affects blood/clotting markers in people with type 2 diabetes. It may help researchers understand whether this form of aspirin could be useful, especially if you’re not currently taking aspirin.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older
- Have type 2 diabetes (you meet it by medication use or specific blood test results like A1c, fasting glucose, or glucose test results)
- Have not taken aspirin regularly: no chronic aspirin in the last 3 months and no aspirin in the last 2 weeks
- Be able and willing to come to all study visits (including a run-in period and the main study)
- Not have a reason/need to take aspirin for heart or blood-vessel disease (no known atherosclerotic disease or related history)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental daily tablet for adults with type 2 diabetes who are not currently on any diabetes medication. It aims to see if the tablet can safely lower blood sugar levels over time.
This trial tests whether older adults with stable heart disease can safely stop taking daily aspirin after two years without increasing the risk of heart attack or stroke. It may help reduce the side effects of long-term aspirin use.
This study looks at how platelets (the cells that help blood clot) may be affected in people with type 2 diabetes. It aims to understand if diabetes changes platelet function, which could help improve heart health in the future.
This trial tests whether an SGLT2 inhibitor pill can help people who have atrial fibrillation (an irregular heartbeat) and type 2 diabetes. You may be eligible if you’re in the right age range, on diabetes pills only, and meet specific heart and lab criteria.
This early-phase study tests a new investigational drug called PATAS, first in healthy volunteers and then in people with type 2 diabetes, to see how safe it is and how the body handles it. It may help future treatments for diabetes, but it does not prove effectiveness yet.
This trial studies whether a low daily dose of aspirin can help protect kidney function in people with early diabetic nephropathy. It aims to slow down the progression of kidney damage.
Hear when a new Platelet Aggregation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.